The WHO website states that the rolling data submission has begun on June 10 and the decision date on EUL is yet to be confirmed. The compa...

"We will review the data of Corbevax in our next meeting slated to happen this month and evaluate if mix and match of vaccines can be allow...

India's drug regulator on Saturday granted approval to Hyderabad-based Biological E's Covid-19 vaccine Corbevax to be allowed as a booster ...

The vaccine can be administered after 6 months of administration of primary vaccination (two doses) of Covaxin or Covishield vaccines for r...

It would result in end users paying a price of Rs 400 a dose, including taxes and administration charges, the company said in a statement. ...

The Drugs Controller General Of India (DCGI) had already approved Corbevax, India's first indigenously developed RBD protein subunit vaccin...

"Our price to the government programme is ₹145, the lowest in the country and possibly the world," Datla said. "It's something we take grea...

Corbevax, is a RBD protein sub-unit vaccine that has been developed with support from the Department of Biotechnology and the Biotechnology...

The Drugs Controller General Of India (DCGI) has already approved Corbevax, which is India's first indigenously developed RBD protein sub-u...

The government is yet to decide on which segment of beneficiaries this new vaccine would be administered.

The subject experts committee (SEC), a body under India's drug regulator, will meet on Monday to review the applications for granting appro...

The government had estimated that Biological would account for 300 million jabs from August to December.

Speaking to reporters on the sidelines of signing a financing agreement with US International Development Finance Corporation (DFC), she sa...

Currently, phase 2/3 clinical trials of the second indigenously developed Corbevax, an RBD protein sub-unit vaccine to be administered in a...

The approval for conducting phase III comparator safety and immunogenicity trial in adults came after the SEC's review of Phase I and II cl...

The phase 2 and 3 clinical trials have be conducted as per approved protocol titled 'A Prospective, Randomised, Double-blind, Placebo contr...

Biological E is working with Baylor College of Medicine (BCM) to make Corbevax. It is undergoing Phase 3 trials and has shown promising res...